Scientists at NGM Bio have uncovered the molecular biology and mechanisms of Growth and Differentiation Factor 15 (GDF15), a hormone regulating body weight. The study reveals potential therapeutics for diseases of excess and insufficient body weight, including obesity and cachexia.
Researchers have identified a novel approach to targeting protein homeostasis in cancer, using p97 inhibitor CB-5083. Preclinical data show CB-5083 induces disease regression in acute myeloid leukemia and demonstrates antitumor activity in solid tumors.
Researchers have discovered a novel epigenetic mechanism that causes the mantled phenotype in oil palms, resulting in reduced oil yields and sterility. A leaf-based test can predict the mantling phenotype at an early stage, enabling the exclusive cultivation of high-performing clonal palms.
A genetic discovery identifies the VIR gene responsible for fruit color change, allowing for more efficient harvesting and increased oil yield. The VIR gene offers a reliable visual cue for oil palm fruit ripeness, paving the way to boost productivity and conserve sensitive wild habitats.
Scientists have mapped the genomes of two oil palm species and identified a critical gene for yield improvement. The discovery has implications for enhancing sustainable palm oil production while reducing pressure on wild rainforests, which account for nearly half of global edible vegetable oil.
A recent Special Focus in Human Vaccines & Immunotherapeutics discusses the mistakes of past cancer vaccine programs and provides critical insights into the future of cancer vaccines. The study emphasizes the importance of antigen discovery and personalized approaches to overcome the challenges of tumor heterogeneity.
The study demonstrated that XMetA markedly reduced elevated fasting blood glucose levels and normalized glucose tolerance in mice experimentally rendered diabetic. After six weeks of treatment, there was a statistically significant reduction in hemoglobin A1c levels in animals treated with XMetA compared to controls.
Researchers found that Toca 511 eliminates tumors in most animals after dosing with 5-FC, providing a dramatic survival benefit. The treatment was well-tolerated and did not cause toxicity over the six-month protocol.